Ermium investors are from very diverse backgrounds : venture capital, industry and technology transfer bringing a wide range of complementary expertises
Founded in July 2009, Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions. Innovative projects from Academia and research institutions, aspiring to meet unmet medical need is an important pillar of the firm’s investment strategy, a second is venture capital financings of innovative young companies in Biotech and MedTech; all with a strong focus on innovative drug development approach.
Eurazeo is a leading global investment company, with a diversified portfolio of €32 billion in assets under management, including nearly €23.2 billion from third parties, invested in 530 companies. With its considerable private equity, venture capital, private debt as well as real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 360 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.
Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore and Sao Paulo.
Eurazeo is listed on Euronext Paris.
Fountain Healthcare Partners is a life science focused venture capital fund with over EUR 300 million (USD 354 million) under management. Fountain invests in entrepreneurs and companies with disruptive technologies or products that have a clear pharmacoeconomic benefit and a defined pathway to commercialisation, value enhancement and exit. Fountain’s main office is in Dublin, Ireland, with a second office in New York. The firm deploys the majority of its capital in Europe, with the balance in the United States.
Domain Therapeutics is committed to discovering and developing innovative cancer immunotherapies, and treatments for neurologic disorders and rare diseases. It is a leading biopharmaceutical company in the field of G Protein- Coupled Receptors (GPCRs), one of the most important class of drug targets.
Domain Therapeutics identifies and develops candidates (allosteric modulators and biased ligands of GPCRs) through its innovative approach and technologies.
Erganeo is a French investment company specializing in disruptive innovations with a positive impact on our society.
Her mission is to accelerate and simplify partnerships between public research bodies and the industrial sector in the pursuit of progress that is ethical and sustainable.